Skip to main content
SpringerLink
Log in

Antipseudomonal therapy in cystic fibrosis: Aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin

  • Article
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

In order to determine the optimal antipseudomonal therapy in patients with cystic fibrosis aztreonam plus amikacin was compared to ceftazidime plus amikacin, and these two-week hospital regimens were followed by oral ciprofloxacin given for four weeks. Fifty-six cases of acute pulmonary exacerbation of the disease in 42 patients associated with isolation ofPseudomonas aeruginosa from the sputum were randomly treated with either aztreonam or ceftazidime (300mg/kg/day i.v.; maximum daily dose 12g) in combination with amikacin (36 mg/kg/day i.v.; maximum daily dose 1,500mg). Other aspects of the two-week treatment were constant. The two therapy groups were comparable in all respects. Both regimens were well tolerated and resulted in similar improvements in clinical, bacteriologic, radiologic and laboratory findings, and pulmonary function. Fifty patients could be reevaluated after subsequent outpatient therapy consisting of oral ciprofloxacin (30 mg/kg/day; maximum daily dose 1,500mg) given for four weeks. During this period, the clinical and laboratory improvements persisted, and the rate of eradication ofPseudomonas aeruginosa from sputum decreased from 62% to 34%. Ciprofloxacin was well tolerated and there was no drug toxicity or serious adverse effect. In the 25 prepubertal patients there was neither subjective nor objective evidence of skeletal drug toxicity. In patients with cystic fibrosis, aztreonam or ceftazidime in combination with amikacin represents an effective and safe systemic anti-pseudomonal therapy. Subsequent oral ciprofloxacin therapy for four weeks prolongs the beneficial effects and is well tolerated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Høiby, N., Friis, B., Jensen, K., Koch, C., Moller, N. E., Stovring, S., Szaff, M.: Antimicrobial chemotherapy in cystic fibrosis patients. Acta Paediatrica Scandinavica 1982, Supplement 301: 75–100.

    Google Scholar 

  2. Marks, M. I.: The pathogenesis and treatment of pulmonary infectious in patients with cystic fibrosis. Journal of Pediatrics 1981, 98: 173–179.

    PubMed  Google Scholar 

  3. Gold, R., Carpenter, S., Heurter, H., Corey, M., Levison, H.: Randomized trial of ceftazidime versus placebo in the management of acute respiratory exacerbations in patients with cystic fibrosis. Journal of Pediatrics 1987, 111: 907–913.

    PubMed  Google Scholar 

  4. Nelson, J. D.: Management of acute pulmonary exacerbations in cystic fibrosis: a critical appraisal. Journal of Pediatrics 1985, 106: 1030–1033.

    PubMed  Google Scholar 

  5. Hyatt, A. C., Chipps, B. E., Kumor, K. M., Mellits, E. D., Lietman, P. S., Rosenstein, B. J.: A double-blind controlled trial of anti-pseudomonas chemotherapy of acute respiratory exacerbations in patients with cystic fibrosis. Journal of Pediatrics 1981, 99: 307–311.

    PubMed  Google Scholar 

  6. Smith, A. L.: Antibiotic therapy in cystic fibrosis: evaluation of clinical trials. Journal of Pediatrics 1986, 108: 866–870.

    PubMed  Google Scholar 

  7. Wientzen, R., Prestidge, C. B., Kramer, R. I., McCracken, G. H., Nelson, J. D.: Acute pulmonary exacerbations in cystic fibrosis: a double-blind trial of tobramycin and placebo therapy. American Journal of Diseases in Children 1980, 134: 1134–1138.

    Google Scholar 

  8. Moss, R. B., Babin, S., Hsu, Y.-P., Blessing-Moore, J., Lewiston, N. J.: Allergy to semisynthetic penicillins in cystic fibrosis. Journal of Pediatrics 1984, 104: 460–466.

    PubMed  Google Scholar 

  9. Adkinson, N. F., Swabb, E. A., Sugerman, A. A.: Immunology of the monobactam aztreonam. Antimicrobial Agents and Chemotherapy 1984, 25: 93–97.

    PubMed  Google Scholar 

  10. Saxon, A., Hassner, A., Swabb, E. A., Wheeler, B., Adkinson, N. F.: Lack of cross-reactivity between aztreonam, a monobactam antibiotic, and penicillin in penicillin-allergic subjects. Journal of Infectious Diseases 1984, 149: 16–22.

    PubMed  Google Scholar 

  11. Jacobus, N. V., Ferreira, M. C., Barza, M.: In vitro activity of aztreonam, a monobactam antibiotic. Antimicrobial Agents and Chemotherapy 1982, 22: 832–838.

    PubMed  Google Scholar 

  12. Bosso, J. A., Black, P. G., Matsen, J. M.: Efficacy of aztreonam in pulmonary exacerbations in cystic fibrosis. Pediatric Infectious Disease Journal 1987, 6: 393–397.

    PubMed  Google Scholar 

  13. Bosso, J. A., Black, P. G.: Controlled trial of aztreonam versus tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis. Pediatric Infectious Disease Journal 1988, 7: 171–176.

    PubMed  Google Scholar 

  14. Schaad, U. B., Wedgwood-Krucko, J., Suter, S., Kraemer, R.: Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis. Journal of Pediatrics 1987, 111: 599–605.

    PubMed  Google Scholar 

  15. Hodson, M. E., Roberts, C. M., Butland, R. J. A., Smith, M. J., Batten, J. C.: Oral ciprofloxacin compared with conventional intravenous treatment forPseudomonas aeruginosa infection in adults with cystic fibrosis. Lancet 1987, i: 235–237.

    Article  Google Scholar 

  16. Jensen, T., Pedersen, S. S., Høiby, N., Koch, C.: Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis. European Journal of Clinical Microbiology 1987, 6: 618–622.

    PubMed  Google Scholar 

  17. Smith, M. J., White, L. O., Bowyer, H., Willis, J., Hodson, M. E., Batten, J. C.: Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis. Antimicrobial Agents and Chemotherapy 1986, 30: 614–616.

    PubMed  Google Scholar 

  18. Kraemer, R., Ruedeberg, A., Kläy, M., Rossi, E.: Relationship between clinical conditions, radiographic findings and pulmonary functions in patients with cystic fibrosis. Helvetica Paediatrica Acta 1979, 34: 417–428.

    PubMed  Google Scholar 

  19. Chrispin, A. R., Norman, A. P.: The systemic evaluation of the chest radiograph in cystic fibrosis. Pediatric Radiology 1974, 2: 101–106.

    Article  PubMed  Google Scholar 

  20. Jones, R. N., Barry, A. L., Gavan, T. L., Washington, J. A.: Susceptibility tests: microdilution and macrodilution broth procedures. In: Lennette, E. H., Balows, A., Hausler, W. J., Shadomy, H. J. (ed.): Manual of clinical microbiology. American Society for Microbiology, Washington, DC, 1985, p. 972–977.

    Google Scholar 

  21. Schaad, U. B., Desgrandchamps, D., Kraemer, R.: Antimicrobial therapy of pseudomonas pulmonary exacerbations in cystic fibrosis. Acta Paediatrica Scandinavica 1986, 75: 128–138.

    PubMed  Google Scholar 

  22. Kraemer, R., Meister, B., Schaad, U. B., Rossi, E.: Reversibility of lung function abnormalities in children with perennial asthma. Journal of Pediatrics 1983, 102: 347–350.

    PubMed  Google Scholar 

  23. Szaff, M., Høiby, N., Flensborg, E. W.: Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronicPseudomonas aeruginosa infection. Acta Paediatrica Scandinavica 1983, 72: 651–657.

    PubMed  Google Scholar 

  24. De Groot, R., Smith, A. L.: Antibiotic pharmacokinetics in cystic fibrosis: differences and clinical significance. Clinical Pharmacokinetics 1987, 13: 228–253.

    PubMed  Google Scholar 

  25. Šcribner, R. K., Marks, M. I., Weber, A. H., Tarpay, M. M., Welch, D. F.: Activities of various beta-lactams and aminoglycosides, alone and in combination, against isolates ofPseudomonas aeruginosa from patients with cystic fibrosis. Antimicrobial Agents and Chemotherapy 1982, 21: 939–943.

    PubMed  Google Scholar 

  26. Wolfson, J. S., Hooper, D. C.: The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrobial Agents and Chemotherapy 1985, 28: 581–586.

    PubMed  Google Scholar 

  27. Woolfrey, B. F., Fox, J. M. K., Quall, C. O., Lally, R. T.: Error rates associated with the use of recently proposed breakpoints for testingPseudomonas aeruginosa versus gentamicin, tobramycin, and amikacin by the standardized disk agar diffusion test. Antimicrobial Agents and Chemotherapy 1983, 24: 764–770.

    PubMed  Google Scholar 

  28. Suter, S., Schaad, U. B., Tegner, H., Ohlsson, K., Desgrandchamps, D., Waldvogel, F. A.: Levels of free granulocyte elastase in bronchial secretions from patients with cystic fibrosis: effect of antimicrobial treatment againstPseudomonas aeruginosa. Journal of Infectious Diseases 1986, 153: 902–909.

    PubMed  Google Scholar 

  29. Suter, S., Schaad, U. B., Morgenthaler, J. J., Chevallier, I., Schnebli, H. P.: Fibronectin-cleaving activity in bronchial secretions of patients with cystic fibrosis. Journal of Infectious Diseases 1988, 158: 89–100.

    PubMed  Google Scholar 

  30. Wolz, C., Kiosz, G., Olge, J. W., Vasil, M. L., Schaad, U. B., Botzenhart, K., Döring, G.:Pseudomonas aeruginosa cross-colonization and persistence in patients with cystic fibrosis. Use of a DNA probe. Epidemiology and Infectiology 1989, 102: 205–214.

    Google Scholar 

  31. Christ, W., Lehnert, T., Ulbrich, B.: Specific toxicologic aspects of the quinolones. Reviews of Infectious Diseases 1988, 10, Supplement 1: 141–146.

    Google Scholar 

  32. Schaad, U. B., Wedgwood-Krucko, J.: Nalidixic acid in children: retrospective matched controlled study for cartilage toxicity. Infection 1987, 15: 165–168.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Inselspital, University of Berne, CH-3010, Berne, Switzerland

    U. B. Schaad, J. Wedgwood-Krucko, K. Guenin, U. Buehlmann & R. Kraemer

Authors
  1. U. B. Schaad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Wedgwood-Krucko
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Guenin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. U. Buehlmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Kraemer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schaad, U.B., Wedgwood-Krucko, J., Guenin, K. et al. Antipseudomonal therapy in cystic fibrosis: Aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin. Eur. J. Clin. Microbiol. Infect. Dis. 8, 858–865 (1989). https://doi.org/10.1007/BF01963771

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01963771

Keywords

Search

Navigation